Legal & General Group
ELVN icon

Legal & General Group’s Enliven Therapeutics ELVN Stock Holding History

Legal & General Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Sell
32,924
-159
-0.5% -$6.75K ﹤0.01% 2023
2026
Q1 		$1.3M Buy
33,083
+6,024
+22% +$167K ﹤0.01% 2055
2025
Q4 		$417K Sell
27,059
-6,706
-20% -$134K ﹤0.01% 2467
2025
Q3 		$691K Buy
33,765
+1,540
+5% +$31K ﹤0.01% 2345
2025
Q2 		$646K Buy
32,225
+11,058
+52% +$209K ﹤0.01% 2376
2025
Q1 		$417K Buy
21,167
+27
+0.1% +$581 ﹤0.01% 2451
2024
Q4 		$476K Buy
21,140
+812
+4% +$21K ﹤0.01% 2473
2024
Q3 		$519K Buy
20,328
+131
+0.6% +$3.03K ﹤0.01% 2451
2024
Q2 		$472K Sell
20,197
-448
-2% -$9.43K ﹤0.01% 2433
2024
Q1 		$363K Buy
20,645
+980
+5% +$15K ﹤0.01% 2548
2023
Q4 		$272K Hold
19,665
– – ﹤0.01% 2648
2023
Q3 		$269K Buy
19,665
+1,610
+9% +$27.1K ﹤0.01% 2648
2023
Q2 		$369K Buy
+18,055
New +$365K ﹤0.01% 2563
2021
Q2 		– Sell
-244
Closed -$8K – 3536
2021
Q1 		$8K Buy
244
+30
+14% +$1.52K ﹤0.01% 3426
2020
Q4 		$19K Buy
214
+58
+37% +$4.87K ﹤0.01% 3108
2020
Q3 		$13K Sell
156
-48
-24% -$4.33K ﹤0.01% 3121
2020
Q2 		$22K Buy
+204
New +$22.8K ﹤0.01% 3025

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Legal & General Group's ELVN Position: Q2 2026 in Review

Legal & General Group reduced its Enliven Therapeutics (ELVN) stake by 0.48% in Q2 2026, selling an estimated $6.75K and leaving 32,924 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2023.

Legal & General Group first reported a position in ELVN in Q2 2020 and has held it in 17 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Legal & General Group held 32,924 shares of Enliven Therapeutics worth $1.67M as of Q2 2026.
  • Legal & General Group sold 159 Enliven Therapeutics shares in Q2 2026, an estimated $6.75K.
  • Enliven Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2023 holding.
  • Legal & General Group first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.